References
- Berra M, Liao LM, Creighton SM, Conway GS. Long-term health issues of women with XY karyotype. Maturitas 2010;65:172–8
- Rossouw JE. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 2002;53:550–7
- van der Schouw YT, van der Graaf Y, Steyerberg EW, et al. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996;347:714–8
- Wellons M. Cardiovascular disease and primary ovarian insufficiency. Semin Reprod Med 2011;29:328–41 [Review]
- Ostberg JE, Donald AE, Halcox JP, et al. Vasculopathy in Turner syndrome: arterial dilatation and intimal thickening without endothelial dysfunction. J Clin Endocrinol Metab 2005;90:5161–6
- Ostberg JE, Storry C, Donald AE, et al. A dose-response study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabolism. Clin Endocrinol (Oxf) 2007;66:557–64
- Kalantaridou SN, Naka KK, Papanikolaou E, et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab 2004;89:3907–13
- Valdiviezo C, Lawson S, Ouyang P. An update on menopausal hormone replacement therapy in women and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2013;20:148–55
- Gaziano JM, Hennekens CH, O'Donnell CJ, et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997;96:2520–5
- Frohlich J, Dobiásová M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 2003;49:1873–80
- Christodoulakos G, Lambrinoudaki I, Panoulis C, et al. Effect of hormone therapy and raloxifene on serum VE-cadherin in postmenopausal women. Fertil Steril 2004;82:634–8
- Matsumoto K, Sera Y, Nakamura H, et al. Serum concentrations of soluble adhesion molecules are related to degree of hyperglycemia and insulin resistance in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2002;55:131–8
- Lip GY, Blann AD. von Willebrand factor and its relevance to cardiovascular disorders. Br Heart J 1995;74:580–3 [Review]
- Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993;14:506–12
- Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008;117:2467–74
- Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am J Epidemiol 1997;146:483–94
- Matthews KA, Meilahn E, Kuller LH, et al. Menopause and risk factors for coronary heart disease. N Engl J Med 1989;321:641–6
- Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 1991;325:756–62
- Papagianni V, Deligeoroglou E, Makrakis E, et al. Response to hormonal treatment of young females with primary or very premature ovarian failure. Gynecol Endocrinol 2011;27:291–9
- Ivanisević M, Vujović S, Drezgić M. Effects of estro-progestagens on lipid and hormonal profiles in women with premature primary ovarian failure. Med Pregl 2005;58:296–300
- Salpeter SR, Walsh JM, Ormiston TM, et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538–54
- Soeki T, Tamura Y, Shinohara H, et al. Elevated concentration of soluble vascular endothelial cadherin is associated with coronary atherosclerosis. Circ J 2004;68:1–5
- El-Mesallamy HO, Hamdy NM, Salman TM, Ibrahim SM. Adiponectin and sE-selectin concentrations in relation to inflammation in obese type 2 diabetic patients with coronary heart disease. Angiology 2012;63:96–102
- van Baal WM, Kenemans P, Emeis JJ, et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil Steril 1999;71:663–70
- Eilertsen AL, Sandvik L, Steinsvik B, Sandset PM. Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. J Thromb Haemost 2008;6:928–34
- Bush DE, Jones CE, Bass KM, et al. Estrogen replacement reverses endothelial dysfunction in postmenopausal women. Am J Med 1998;104:552–58
- Vehkavaara S, Hakala-Ala-Pietilä T, Virkamäki A, et al. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation 2000;102:2687–93
- Kelemen M, Vaidya D, Waters DD, et al. Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial. Atherosclerosis 2005;179:193–200
- Tremollieres FA, Cigagna F, Alquier C, et al. Effect of hormone replacement therapy on age-related increase in carotid artery intima-media thickness in postmenopausal women. Atherosclerosis 2000;153:81–8
- Westendorp IC, in ‘t Veld BA, Bots ML, et al. Hormone replacement therapy and intima-media thickness of the common carotid artery: the Rotterdam study. Stroke 1999;30:2562–7
- Byington RP, Furberg CD, Herrington DM, et al., Heart and Estrogen/Progestin Replacement Study Research Group. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol 2002;22:1692–7